We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer
News

Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer

Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer
News

Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Biomarkers for Ovarian Cancer."

The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.

This represents the fifteenth biomarker patent granted or allowed for Vermillion, four of which support the company's ovarian cancer franchise and its flagship product, OVA1®.

"Our innovative biomarker research continues to build Vermillion's platform of proprietary diagnostic tools, which is supported by key patents," said Donald Munroe, Ph.D., the company's chief science officer and VP of research & development.

Munroe continued, "We believe these tools represent the best diagnostic tools available today in the diagnosis and management of ovarian cancer, which is the leading cause of gynecologic cancer mortality."

Advertisement